Glaxo
Executive Summary
Former Duke University professor and Sphinx Pharmaceuticals founder Robert Bell, PhD, named VP-research of Glaxo, Inc. Bell, a biochemist, will direct discovery research in cancer and metabolic disease as well as development of "products in all therapeutic areas." He replaces Leslie Hudson, PhD, who is now chief operating officer of Repligen. Senior VP/Director of the Glaxo Research Institute James Niedel, MD/PhD, will become group R&D director and managing director of Glaxo R&D in the U.K.; Niedel will be replaced by Terence Eaves, PhD, formerly development director of Glaxo R&D. James Palmer, MD, currently senior VP of Glaxo, Inc., will become Glaxo group development director